Please assess the completion status of the following clinical trial:

Trial Title: Trachoma Amelioration in Northern Amhara (TANA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~• All residents residing in the state-teams which are randomly selected for this study.~Exclusion Criteria:~* Pregnant women~* Children under 6 months of age~* All those who are allergic to macrolides or azalides~* Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)~Individuals in these three exclusion criteria will not be given the study antibiotic azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day, topically to both eyes, for six weeks. Note that the exclusion criteria refer to the exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and examinations.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: OTHER): Annual mass treatment
- B (Type: OTHER): Biannual mass treatment
- C (Type: EXPERIMENTAL): Mass administration of antibiotic; treatment of children (1-10 years of age) only
- D (Type: NO_INTERVENTION): Delayed initiation of mass administration of antibiotic
- F (Type: OTHER): One-time mass administration only
- G (Type: EXPERIMENTAL): One-time mass administration of antibiotics, plus intensive latrine construction

Based on this trial design, predict the completion outcome and termination type (if applicable).